A Randomized, Multicenter, Double-Blind Phase III Study of PD-0332991 Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women with ER (+), HER2 (-) Breast Cancer who have not Received any Prior Systemic Anti-Cancer Treatment for Advanced Disease
What is the purpose of this trial?
To demonstrate that the combination of PD-0332991 with letrozole is superior to placebo plus letrozole in prolonging PFS in postmenopausal women with ER(+)/HER2 (-) advance breast cancer who have not received any prior systemic anti-cancer therapies for their advanced/metastatic disease.
- Pfizer Inc., U.S. Pharmaceuticals Group
- Last Updated:
- Study HIC#: